

Next steps: developing HTA for sustainable healthcare systems

A perspective from countries with well-established HTA systems

Kalipso Chalkidou,
NICE International

Challenges and opportunities

- HTA and P&R policies: evidence-based pricing?
 - Value Based Pricing
 - Risk-Sharing and Patient Access Schemes
 - Coverage with Evidence Development
- HTA in the recession: evidence-based disinvestment?
 - No more growth money...
 - Avoid crowding out of effective technologies through more “No”s and a recalibrated threshold
- HTA and social values: evidence-based morals?
 - HTA is not devoid of values (neither should it be)
 - Elicit, incorporate and communicate judgements to politicians, service users and tax-payers

And of course...HTA and innovation

- "The industry shouldn't be afraid of comparative effectiveness. They would be better off embracing it, and trying to use it rationally, rather than fighting it. The solution isn't marketing. They should be focusing on innovation."
- Brian Storm, Senior Fellow, Leonard Davis Institute

- "They may save themselves if they come up with a wonderful product at a wonderful price, but they may need to light a votive candle."
- Mark Pauly, Wharton Healthcare Management Professor

Thank you!

kalipso.chalkidou@nice.org.uk